Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. Issue 10 (4th February 2019) - Ammoun, Sylwia; Evans, D Gareth; Hilton, David A; Streeter, Adam; Hayward, Christopher; Hanemann, C Oliver